Literature DB >> 2831281

Intranasal immunization of hamsters with envelope glycoproteins of human parainfluenza virus type 3.

R Ray1, B J Glaze, Z Moldoveanu, R W Compans.   

Abstract

Envelope glycoproteins of human parainfluenza virus type 3 (PIV-3) were selectively solubilized with n-octyl beta-D-glucopyranoside and reconstituted into lipid vesicles by dialysis of the detergent. The efficacy of the glycoprotein preparation as a subunit vaccine when administered to hamsters intranasally or subcutaneously was compared. Animals receiving four intranasal immunizations with 5 micrograms of the glycoprotein preparation were completely resistant to challenge infection. Only partial protection, however, was observed in animals immunized subcutaneously with the same dose of antigen. The local glycoprotein-specific IgA response was significantly higher in intranasally immunized animals and was implicated in resistance to challenge infection.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2831281     DOI: 10.1093/infdis/157.4.648

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  6 in total

Review 1.  Nasal lymphoid tissue, intranasal immunization, and compartmentalization of the common mucosal immune system.

Authors:  H Y Wu; M W Russell
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

2.  Antibody responses of humans and nonhuman primates to individual antigenic sites of the hemagglutinin-neuraminidase and fusion glycoproteins after primary infection or reinfection with parainfluenza type 3 virus.

Authors:  K L van Wyke Coelingh; C C Winter; E L Tierney; S L Hall; W T London; H W Kim; R M Chanock; B R Murphy
Journal:  J Virol       Date:  1990-08       Impact factor: 5.103

Review 3.  Parainfluenza viruses.

Authors:  Kelly J Henrickson
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

4.  Oral immunization of rats with proteinoid microspheres encapsulating influenza virus antigens.

Authors:  N Santiago; S Milstein; T Rivera; E Garcia; T Zaidi; H Hong; D Bucher
Journal:  Pharm Res       Date:  1993-08       Impact factor: 4.200

5.  Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children.

Authors:  Ruth A Karron; Bhagvanji Thumar; Elizabeth Schappell; Sonja Surman; Brian R Murphy; Peter L Collins; Alexander C Schmidt
Journal:  Vaccine       Date:  2011-12-14       Impact factor: 3.641

6.  Development of oligomannose-coated liposome-based nasal vaccine against human parainfluenza virus type 3.

Authors:  Kyosuke Senchi; Satoko Matsunaga; Hideki Hasegawa; Hirokazu Kimura; Akihide Ryo
Journal:  Front Microbiol       Date:  2013-11-26       Impact factor: 5.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.